Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)

NCT02615691 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT02615691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02615691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Lead sponsor
Baxalta now part of Shire
Phase
Phase 3
Overall status
Completed
Start date
November 12, 2015
Completion date
October 29, 2024
Enrollment
120 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a